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Abstract
Background: Recently, it has been hypothesized that type 2 diabetes might interfere with acute
intravenous thrombolysis effectiveness as estimated by angiographic or electrocardiographic cri-
teria. In our study, we compared the thrombolytic effect of streptokinase infusion between
diabetic and non-diabetic myocardial infarction (MI) patients.
Methods: In a prospective interventional study, 240 consecutive patients who were admitted
to the emergency ward and diagnosed with ST-elevation MI (STEMI) were enroled and
classified into diabetics (n = 85) and non-diabetics (n = 155). Streptokinase was given to
each patient at a dose of 1.5 million units in 1 h. Twelve-lead ECG was recorded immediately
before the start of thrombolytic therapy and at 180 min afterwards for the patients with
STEMI. The ST-segment elevation resolution was calculated and stratified as complete reso-
lution (> 70% ST-resolution), partial resolution (30–70% ST-resolution), or failed resolution
(< 30% ST-resolution).
Results: Complete ST-resolution occurred in 31.6% of diabetic and 51.0% of non-diabetic
patients, respectively (p < 0.001). The incidence of partial ST-resolution in diabetic and non-
-diabetic patients was 40.5% and 40.0%, whereas 27.8% of patients in the diabetic group and
9.0% of patients in the non-diabetic group showed failed ST resolution. ST-resolution was
independent of the location of MI. Multivariate analysis showed that diabetes mellitus, as well
as higher Killip class and lower ejection fraction, could effectively predict ST-resolution failure.
Conclusions: Failure of ST-segment resolution 180 min after streptokinase infusion is
notably higher in diabetic vs non-diabetic patients. This failure rate is correlated with higher
Killip class and lower ejection fraction. (Cardiol J 2012; 19, 2: 168–173)
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Introduction
The main purpose of thrombolysis in acute
myocardial infarction (MI) is early and complete
reperfusion. Therefore, incomplete or delayed rep-
erfusion is associated with an increased risk of death
and left ventricular (LV) dysfunction. The time to
reperfusion and complete reperfusion remain the key
determinants for appropriate outcome of cardiovas-
cular events. Although evidence over recent de-
cades has confirmed the improvement in outcomes
of cardiovascular disease in the general population
by various therapeutic interventions, these bene-
fits have not been paralleled in diabetic patients [1].
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These patients are considerably at risk of major
complications and death after acute ST-segment
elevation myocardial infarction (STEMI), independent
of other risk factors for coronary artery disease [2].
In fact, although thrombolytic therapy might be
accompanied by beneficial effects in diabetic pa-
tients, the rates of sustained MI, re-occlusion, and
mid-term mortality of treated patients remain worse
in diabetic than non-diabetic patients [3–6]. This
more adverse outcome can be due to the appear-
ance of impaired post-thrombolysis LV function and
prognosis [7].
In this context, some studies have found that
thrombolytic agents unquestionably reduce the
mortality of patients with a STEMI among patients
with diabetes, but others have revealed that diabetic
patients were less likely to receive thrombolysis,
despite having a greater potential for benefit [8–12].
Thus, it is hypothesized that type 2 diabetes might
interfere with the effectiveness of acute intrave-
nous thrombolysis, as estimated by angiographic or
electrocardiographic criteria [13]. In the current
study, we compared the thrombolytic effect of
streptokinase between diabetic and non-diabetic MI
patients.
Methods
In a prospective interventional study, 240 con-
secutive patients who were admitted to the emer-
gency ward of the Shafa hospital in Kerman between
April 2006 and October 2007 with typical chest pain
or other clinical manifestations of MI within 6 h of
the onset of chest pain were included into the study.
The final diagnosis of STEMI was confirmed using
electrocardiogram (ECG) special changes and ele-
vated cardiac enzymes that were checked at the ad-
mission time. Included patients had the following
criteria: 1) typical chest pain lasting ≥ 30 min;
2) ST-segment elevation ≥ 0.2 mV in two or more con-
tiguous precordial leads (for the diagnosis of ante-
rior wall MI) or in leads V1–V3 (for the diagnosis of
anteroseptal wall MI) as well as ≥ 0.1 mV in II, III,
and aVF leads (for the diagnosis of inferior wall MI)
on the admission ECG; 3) increase in serum creat-
ine kinase (CK) level more than twice the normal
value. Exclusion criteria were: late presentation,
more than 6 h since the onset of chest pain, history
of previous MI, not treated with streptokinase, or
left bundle branch block (LBBB) pattern in ECG.
All patients signed research study informed consent
documents, and the study was approved by the
Ethics Committee of the Internal Review Board of
Kerman University of Medical Sciences.
Demographic characteristics and clinical crite-
ria of the patients were extracted from previously
recorded files, as well as face-to-face interviewing
if required, and entered into a computerized data-
base. The patients were given self-administered
questionnaires about their medical history includ-
ing general characteristics, coronary artery disease
risk factors: opium addiction (consumption of inha-
latory opium more than three times per week and/
/or oral opium daily) [14], current smoking history
(regularly smoking a tobacco product/products one
or more times per day or having smoked in the
30 days prior to admission) [15], hypertension (sys-
tolic blood pressure ≥ 140 mm Hg and/or diastolic
≥ 90 mm Hg and//or on antihypertensive treatment)
[16], diabetes mellitus (symptoms of diabetes plus
at least one of the following: plasma glucose con-
centration ≥ 11.1 mmol/L, fasting plasma glucose
≥ 7.0 mmol/L, and 2-hpp ≥ 11.1 mmol/L) [17], and
Killip class.
Streptokinase was given to each patient at
a dose of 1.5 million units, diluted in 100 mL of nor-
mal saline, in 1 h. Twelve-lead ECG was recorded
immediately before the start of thrombolytic thera-
py and 180 min afterwards for patients with STEMI.
Fasting plasma glucose was recorded from all pa-
tients on the morning of the day following hospital
admission. Participants were classified into two
groups: 1) diabetic patients (n = 85), and 2) non-
-diabetic patients (n = 155).
ST-segment elevation resolution was calculat-
ed as the initial sum of ST-segment elevation (on
pre-treatment ECG) minus the sum of ST-segment
elevation on the second ECG (180 min after strep-
tokinase infusion) divided by the initial sum of
ST-segment elevation and expressed as a percent-
age. Complete ST-resolution (≥ 70% ST-resolu-
tion) in patients with acute MI most likely identi-
fies patients with successful reperfusion following
streptokinase therapy, and these patients proved to
be a very low-risk group with good prognosis. But
failed or no ST-resolution (< 30% ST-resolution)
identifies patients with failed myocardial reperfu-
sion, which means that these patients have a high-
er risk for an adverse outcome [18]. However,
partial ST-resolution (< 70% to 30%) is related to
impairment of reperfusion at the myocardial level,
reflecting the unpredictable effect of streptokinase
[19, 20]. Thus, the ST-segment elevation resolu-
tion was stratified into three categories: a) complete
ST resolution (≥ 70% reduction of ST elevation);
b) partial ST resolution (< 70% to 30% reduction
of ST elevation); and c) failed ST resolution (< 30%
reduction of ST elevation).
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Statistical analysis
Results were reported as mean ± standard
deviation (SD) for the quantitative variables and
percentages for the categorical variables. The
groups were compared using the Student’s t-test for
the continuous variables and the c2 test (or Fisher’s
exact test if required) for the categorical variables.
Predictors exhibiting a statistically significant re-
lation with ST resolution status in the two diabetic
and non-diabetic groups in univariate analyses were
taken for multivariate logistic regression analysis
to investigate their independence as predictors.
Odds ratio (OR) and 95% confidence intervals (CI)
were calculated. A p values of 0.05 or less were con-
sidered statistically significant. All the statistical
analyses were performed using SPSS version 16.0
(SPSS Inc., Chicago, IL, USA) and SAS version 9.1
for Windows (SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics and laboratory para-
meters of the two study subjects are summarized in
Table 1. Diabetics were older than the non-diabetic
participants, and the history of hypertension was
more prevalent in the former group. The overall
prevalence of current smoking and regular opium use
were higher in the non-diabetics. Diabetic patients
suffered more from cardiac tachyarrhythmia, and left
ventricular ejection fraction (LVEF) was significantly
higher in non-diabetics. The two study groups were
matched with respect to family history of coronary
disease, Killip class, and current measured blood
pressure. Regarding laboratory indices, individuals
with diabetes had a lower serum hemoglobin level
than the non-diabetics, whereas there were no sig-
nificant differences in the serum levels of total cho-
lesterol and low density lipoprotein between the two
groups. Anterior MI appeared in 41.7% of the dia-
betics and 30.3% of the non-diabetics, so was slight-
ly more frequent in diabetic patients (p = 0.076).
Inferior MI was similarly observed in diabetic and
non-diabetic groups (32.1% vs 39.4%, p = 0.262)
(Fig. 1). Figure 2 shows a comparison of ST-resolu-
tion at 180 min after streptokinase between non-dia-
betic and diabetic MI patients, where complete ST-
-resolution occurred in 31.6% of diabetic and 51.0%
of non-diabetic patients, respectively (p < 0.001).
Table 1. Baseline characteristics and laboratory data in diabetic and non-diabetic patients.
Characteristics Diabetics  (n = 85) Non-diabetics  (n = 155) P
Male gender 54 (63.5) 133 (85.8) < 0.001
Age [years] 59.6 ± 9.4 54.2 ± 12.3 < 0.001
History of hypertension 32 (37.6) 35 (22.6) 0.013
Family history of CAD 16 (20.0) 28 (20.0) 0.999
Current smoking 19 (22.4) 79 (51.0) < 0.001
Opium use 33 (38.8) 92 (59.4) 0.007
Killip class
I 50 (61.7) 114 (75.5)
II 24 (29.6) 26 (17.2) 0.177
III 5 (6.2) 5 (3.3)
IV 2 (2.5) 6 (4.0)
Heart rate > 100/min 32 (38.1) 25 (16.1) < 0.001
Systolic BP > 140 mm Hg 30 (36.1) 42 (27.1) 0.148
Diastolic BP > 100 mm Hg 65 (77.4) 118 (76.1) 0.827
LVEF (%) 42.2 ± 9.0 46.7 ± 9.0 < 0.001
Laboratory parameters:
Fasting blood sugar 220.5 ± 88.0 102.5 ± 16.3 < 0.001
Total cholesterol 214.0 ± 52.1 201.7 ± 60.3 0.105
Triglyceride 190.6 ± 135.9 149.7 ± 92.4 0.007
Low density lipoprotein 115.9 ± 33.1 118.2 ± 38.7 0.777
High density lipoprotein 51.0 ± 25.6 44.3 ± 10.8 0.102
Serum hemoglobin 14.6 ± 1.9 15.9 ± 3.7 0.001
Serum hematocrit 48.3 ± 33.3 47.0 ± 8.9 0.708
Serum platelet 229.9 ± 97.0 222.6 ± 78.5 0.559
CAD — coronary artery disease; BP — blood pressure; LVEF — left ventricular ejection fraction
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The incidence of partial ST-resolution in dia-
betic and non-diabetic patients was 40.5% and
40.0%, where 27.8% of patients in the diabetic group
and 9.0% of patients in the non-diabetic group
showed failed ST resolution. ST-resolution was
independent of the location of MI (p = 0.276)
(Fig. 3). Multivariate analysis showed that diabe-
tes mellitus, as well as higher Killip class and low-
er EF, could effectively predict ST resolution fail-
ure (Table 2).
Discussion
Some researchers have revealed similar angio-
graphic [21] or electrocardiographic [22] success-
es in both diabetic and non-diabetic patients, while
other studies have shown that diabetics have less
complete resolution of ST elevation than non-dia-
betics [23]. To evaluate this issue, it was hypothe-
sized that diabetes might interfere with the effec-
tiveness of intravenous thrombolysis, as estimat-
ed by angiographic or electrocardiographic criteria.
The present study addressed the thrombolytic ef-
fect of streptokinase in type 2 diabetic STEMI pa-
tients and compared it with non-diabetic STEMI
patients in the same setting.
In a recent study of ST resolution by thrombolytic
versus primary coronary intervention [24], it was
shown that ST-segment resolution following throm-
bolytic therapy was: complete 51.9%, partial 26.6%
and failed resolution in 21.5% of acute MI patients
90 min after the initiation of fibrinolytic therapy.
In our trial, we obtained similar results in non-
-diabetic MI patients, where 51.0% of patients
showed complete resolution, 40.0% partial resolu-
tion, and 9.0% showed failed resolution. But in cases
of diabetic STEMI, 31.6% of patients showed com-
plete resolution, 40.5% partial resolution, and 27.8%
failed resolution. In our study, more ‘complete ST-
-resolution’ was seen in non-diabetic patients, while
type 2 diabetic subjects presented with a significant-
ly higher incidence of failed ST-resolution than non-
-diabetic subjects.
Overall, ST-segment resolution was signifi-
cantly more complete in non-diabetic than in dia-
betic patients. Stress hyperglycemia has a detri-
mental effect on thrombolytic outcome after acute
MI. Mortality may increase, especially in non-dia-
betic patients. Diabetes can be differentiated from
stress hyperglycemia with certainty only after the
acute phase of the infarction. Thus, any attempt to
identify undiagnosed diabetes in our study would
have been biased, because patients must survive
the acute phase to be diagnosed. Besides, adjunc-
Figure 1. Location of myocardial infarction (MI) in dia-
betes and non-diabetes.
Figure 2. ST-segment resolution in diabetes and non-
diabetes.
Figure 3. ST-segment resolution in different locations
of myocardial infarction (MI).
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tive therapies by aspirin have been suggested as
being important for reducing mortality in STEMI.
The administration of aspirin just prior to streptoki-
nase infusion might have contributed somewhat to
the overall success rate of streptokinase efficacy,
but certainly did not influence the relative success/
/failure rates in each time segment.
Other determinants of ST-resolution failure in
our study were higher Killip class and lower EF. In
some studies, global LV systolic function and sur-
vival after thrombolysis have been divergent be-
tween diabetic and non-diabetic patients [25, 26].
Impairment of regional LV functions in a non-in-
farct-related area, which was more common among
diabetic patients) [27], and other factors intrinsic
to diabetics, such as diastolic dysfunction and myo-
cardial fibrosis, may contribute to the higher ob-
served ST resolution failure rate.
Conclusions
Our study indicates that the failure of ST-seg-
ment resolution 180 min after streptokinase infu-
sion is notably higher in diabetic vs non-diabetic
patients. This failure rate is also correlated with
higher Killip class and lower EF.
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